COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Pharmaceutical Composition and Administrations Thereof

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. 1. A method of treating or lessening the severity of Osteoporosis or Osteopenia in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein Compound 1 is substantially amorphous Compound 1 or a pharmaceutically acceptable salt thereof.3. The method of claim 1 , wherein Compound 1 is amorphous Compound 1 or a pharmaceutically acceptable salt thereof.4. The method of claim 1 , wherein administering Compound 1 to said patient comprises administering a pharmaceutical composition claim 1 , in which the pharmaceutical composition comprises about 34.1 wt % of a solid dispersion by weight of the composition claim 1 , wherein the dispersion comprises about 80 wt % of substantially amorphous or amorphous Compound 1 by weight of the dispersion claim 1 , about 19.5 wt % of HPMCAS by weight of the dispersion claim 1 , and about 0.5 wt % SLS by weight of the dispersion; about 30.5 wt % of microcrystalline cellulose by weight of the composition; about 30.4 wt % of lactose by weight of the composition; about 3 wt % of sodium croscarmellose by weight of the composition; about 0.5 wt % of SLS by weight of the composition; about 0.5 wt % of colloidal silicon dioxide by weight of the composition; and about 1 wt % of magnesium stearate by weight of the composition.5. The method of claim 4 , wherein the pharmaceutical composition contains 150 mg of Compound 1.6. A method of providing bone healing and/or bone repair in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.7. The method of claim 6 , wherein ...

Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Pharmaceutical Composition and Administrations Thereof

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. 1. A method of treating or lessening the severity of Osteoporosis or Osteopenia in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein Compound 1 is substantially amorphous Compound 1 or a pharmaceutically acceptable salt thereof.3. The method of claim 1 , wherein Compound 1 is amorphous Compound 1 or a pharmaceutically acceptable salt thereof.4. The method of claim 1 , wherein administering Compound 1 to said patient comprises administering a pharmaceutical composition claim 1 , in which the pharmaceutical composition comprises about 34.1 wt % of a solid dispersion by weight of the composition claim 1 , wherein the dispersion comprises about 80 wt % of substantially amorphous or amorphous Compound 1 by weight of the dispersion claim 1 , about 19.5 wt % of HPMCAS by weight of the dispersion claim 1 , and about 0.5 wt % SLS by weight of the dispersion; about 30.5 wt % of microcrystalline cellulose by weight of the composition; about 30.4 wt % of lactose by weight of the composition; about 3 wt % of sodium croscarmellose by weight of the composition; about 0.5 wt % of SLS by weight of the composition; about 0.5 wt % of colloidal silicon dioxide by weight of the composition; and about 1 wt % of magnesium stearate by weight of the composition.5. The method of claim 4 , wherein the pharmaceutical composition contains 150 mg of Compound 1.6. A method of providing bone healing and/or bone repair in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.7. The method of claim 6 , wherein ...

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 110-. (canceled)11. A solid dispersion comprising amorphous N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide.12. (canceled)13. (canceled)14. The solid dispersion of claim 11 , further comprising a surfactant claim 11 , polymer claim 11 , or inert pharmaceutically acceptable substance.15. The solid dispersion of claim 11 , further comprising a polymer.16. (canceled)17. (canceled)18. (canceled)19. The solid dispersion of claim 15 , wherein the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS).20. (canceled)21. The solid dispersion of claim 15 , wherein the polymer is present in an amount of from about 10% by weight to about 80% by weight.22. The solid dispersion of claim 21 , wherein the polymer is present in an amount of less than about 70% by weight.23. (canceled)24. (canceled)25. The solid dispersion of claim 11 , wherein the N-[2 claim 11 ,4-bis(1 claim 11 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 11 ,4-dihydro-4-oxoquinoline-3-carboxamide is present in an amount of from about 10% by weight to about 80% by weight.26. (canceled)27. (canceled)28. The solid dispersion of claim 11 , further comprising a surfactant.29. The solid dispersion of claim 28 , wherein the surfactant is sodium lauryl sulfate.30. The solid dispersion of wherein the surfactant is present in an amount from about 0.1 to about 5%.31. The solid dispersion of claim 30 , wherein the surfactant is present in 0.5%.32. (canceled)33. (canceled)34. The solid dispersion according to claim 11 , wherein the solid dispersion is obtained by spray drying.35. (canceled)36. (canceled)37. A pharmaceutical composition comprising amorphous N-[2 claim 11 ,4-bis(1 claim 11 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 11 ,4-dihydro-4-oxoquinoline-3- ...

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Pharmaceutical compositions including N-[2,4-bis( U -dimethyicthyi)-5- hydrox^[Lambda]enylJ-i ^dihydro^-oxoquinoiineO-carboxamicie (Compound 1 ) and methods of using such compositions are described herein.

Internet and related networks, a method of and system for substitute use of checksum field space in information processing datagram headers for obviating processing speed and addressing space limitations and providing other features

In Internet and related networks, a method of and system for substitute use of the normal checksum field space in information processing (IP) datagram headers for obviating current processing time and addressing space limitations, involving replacing the current checksum usage in the checksum field with its attendant processing time with further source host and destination host addresses of lesser processing time, thereby increasing the address space for the network and decreasing the require header processing time, and/or providing space for autonomous system numbers, a higher layer protocol-based routing information (including of the MPLS type) or for Virtual Private Networks Indentifiers in the header.

Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 1. Solid amorphous N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide.2. The solid amorphous N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide of claim 1 , comprising less than about 15% crystalline N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide.3. A preparation of amorphous N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide substantially free of crystalline N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide.4. The preparation of claim 3 , further comprising a surfactant claim 3 , polymer claim 3 , or inert pharmaceutically acceptable substance.5. The preparation of or claim 3 , wherein the preparation comprises a solid dispersion claim 3 , a mixture or a liquid dispersion.65. The preparation of one of - claims 3 , wherein the preparation comprises solid particles.76. The preparation of one of - claims 3 , comprising less than about 15% of crystalline N-[2 claims 3 ,4-bis(1 claims 3 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claims 3 ,4-dihydro-4-oxoquinoline-3-carboxamide.87. The preparation of one of - claims 3 , wherein the amorphous N-[2 claims 3 ,4-bis(1 claims 3 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claims 3 ,4-dihydro-4-oxoquinoline-3-carboxamide has a particle size distribution of D10 claims 3 , less than 5 μm.98. The preparation of one of - claims 3 , wherein the amorphous N-[2 claims 3 ,4-bis(1 claims 3 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claims 3 ,4-dihydro-4-oxoquinoline-3-carboxamide have a particle size distribution of D50 claims 3 , less than 17 μm. ...

Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 1104-. (canceled)105. A crystal form of N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide , characterized by one or more peaks at about 6.2 , about 7.6 , about 12.3 , and about 18.0 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation (2Θ).106. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 8.40.107. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 11.0.108. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 14.8.109. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 16.1.110. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 17.1.111. The crystal form of claim 105 , wherein the crystal form of N-[2 claim 105 ,4-bis(1 claim 105 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 105 ,4-dihydro-4-oxoquinoline-3-carboxamide is further characterized by a peak at about 18.6.112. The crystal form of claim 105 , wherein the crystal form of ...

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 177.-. (canceled)78. A pharmaceutical pack or kit comprising substantially amorphous N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide and a pharmaceutically acceptable carrier.79132.-. (canceled)133. The pharmaceutical pack or kit according to comprising substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , wherein the substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide comprises less than about 15% crystalline N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxypheny]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , and a pharmaceutically acceptable carrier.134. The pharmaceutical pack or kit according to claim 78 , wherein the substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide comprises less than about 5% crystalline N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , and a pharmaceutically acceptable carrier.135. The pharmaceutical pack or kit according to comprising amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxypheny]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide and a pharmaceutically acceptable carrier. This application claims priority under 35 USC § 119(e) to U.S. Patent Application Ser. No. 60/754,381, filed on Dec. 28, 2005, the entire contents of which are hereby incorporated by reference.The present invention relates to solid state forms, for example, crystalline and amorphous forms, of N-[2,4-bis(1,1- ...

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 1. A method for treating cystic fibrosis in a mammal comprising administering a solid pharmaceutical composition comprising amorphous N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide and less than about 30% crystalline N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide in combination with an additional therapeutic agent.2. The method of claim 1 , wherein the additional agent is selected from a mucolytic agent claim 1 , a bronchodilator claim 1 , an antibiotic claim 1 , an anti-infective claim 1 , an anti-inflammatory claim 1 , a cystic fibrosis transmembrane conductance regulator (CFTR) modulator claim 1 , and a nutritional agent.3. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.4. The method of claim 1 , wherein the composition is in the form of a solid dispersion.5. The method of claim 1 , wherein the composition comprises less than about 5% claim 1 , based on the composition claim 1 , of crystalline N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide.6. The method of claim 1 , wherein the composition further comprises a polymer.7. A method for treating cystic fibrosis in a mammal comprising administering 100% amorphous N-[2 claim 1 ,4-bis(1 claim 1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 1 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 1 , as determined by Cu K alpha radiation (2Θ) X-ray powder diffraction claim 1 , in combination with an additional therapeutic agent.8. The method of claim 7 , wherein the additional therapeutic agent is selected from a mucolytic agent claim 7 , a bronchodilator claim 7 , an antibiotic claim 7 , an anti-infective ...

SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE

The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. 177.-. (canceled)78. A pharmaceutical pack or kit comprising substantially amorphous N-[2 ,4-bis(1 ,1-dimethylethyl)-5-hydroxyphenyl]-1 ,4-dihydro-4-oxoquinoline-3-carboxamide and a pharmaceutically acceptable carrier.79132.-. (canceled)133. The pharmaceutical pack or kit according to comprising substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , wherein the substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide comprises less than about 15% crystalline N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxypheny]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , and a pharmaceutically acceptable carrier.134. The pharmaceutical pack or kit according to claim 78 , wherein the substantially amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide comprises less than about 5% crystalline N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxyphenyl]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide claim 78 , and a pharmaceutically acceptable carrier.135. The pharmaceutical pack or kit according to comprising amorphous N-[2 claim 78 ,4-bis(1 claim 78 ,1-dimethylethyl)-5-hydroxypheny]-1 claim 78 ,4-dihydro-4-oxoquinoline-3-carboxamide and a pharmaceutically acceptable carrier. This application claims priority under 35 USC § 119(e) to U.S. Patent Application Ser. No. 60/754,381, filed on Dec. 28, 2005, the entire contents of which are hereby incorporated by reference.The present invention relates to solid state forms, for example, crystalline and amorphous forms, of N-[2,4-bis(1,1- ...

Solid forms of n- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide

Una dispersión sólida que comprende N-[2,4-bis(1,11-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3-carboxamida amorfa. A solid dispersion comprising amorphous N- [2,4-bis (1,11-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide.

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Pharmaceutical composition and administrations thereof.

La presente invención se relaciona con composiciones farmacéuticas que comprenden una dispersión sólida de N-[2,4-Bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquin olina-3-carboxamida, los métodos para elaborar las composiciones farmacéuticas de la presente invención, y los métodos para administrar las composiciones farmacéuticas de la presente invención.

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

N- [2,4-DIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOKINOLINO-3-CARBOXAMIDE TABLE FOR USE FOR USE

Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν διασπορά στερεού του Ν-[2,4-Δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3 καρβοξαμιδίου, μεθόδους βιομηχανικής κατασκευής φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης και μεθόδους χορήγησης φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης. The present invention relates to pharmaceutical compositions comprising a solid dispersion of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide solid, methods for the manufacture of pharmaceuticals compositions of the present invention and methods of administering pharmaceutical compositions of the present invention.

Tablet formulation of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the the treatment of cystic fibrosis

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1 ,1 -dimethylethyl)-5 hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Pharmaceutical compositions including N-[2,4-bis( U -dimethyicthyi}-5- hydrox^ΛϵnylJ-i ^dihydro^-oxoquinoiineO-carboxamicie (Compound 1 ) and methods of using such compositions are described herein.

Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound I ), and pharmaceutical compositions thereof.

Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis

Tabletformulering af N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid til anvendelse til behandling af cystisk fibrose

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου

Η παρούσα εφεύρεση αφορά σε στερεάς κατάστασης μορφές του Ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδίου (Ένωση 1), φαρμακευτικές συνθέσεις αυτού και μεθόδους με αυτό.

Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Formulacija tablete N-(2,4-bis(1,1-dimetiletil)-5-hidroksifenil)-1,4-dihidro-4-oksokinolin -3-karboksamida za uporabo v zdravljenju cistične fibroze